The addition of apalutamide (Erleada) to secondary radiotherapy (SRT) produced clinically meaningful benefits among patients with recurrent prostate cancer and luminal B tumors, supporting PAM50 as a validated biomarker that may guide the use of…
The addition of apalutamide (Erleada) to secondary radiotherapy (SRT) produced clinically meaningful benefits among patients with recurrent prostate cancer and luminal B tumors, supporting PAM50 as a validated biomarker that may guide the use of…